The Causal Association Between Medication Intake and Increased Risk of Psoriasis
Keywords:
psoriasis, medicine intake, Mendelian randomization, risk factorsAbstract
Introduction: Psoriasis is a chronic, inflammatory, and papulo-squamous skin disorder without a radical cure. Although previous observational analyses have discovered a relationship between medication intake and increased risk of psoriasis, they are susceptible to confounders.
Objectives: We intend to ascertain if there is a causal association between specific medication intake and increased risk of psoriasis by utilizing the Mendelian randomization (MR) method.
Methods: We obtained the genome-wide association study (GWAS) data for medication intake (23 types, N = 1809) from UK Biobank samples. And we sourced the GWAS data for psoriasis from the 8th release of the FinnGen database, which included 8,075 psoriasis cases and 330,975 healthy control cases. Then a two-sample MR study was performed to determine their causal association, and inverse-variance-weighted MR (IVW-MR) was applied to calculate the effect estimates.
Results: The IVW-MR analysis uncovered a positive correlation between the intake of HMG CoA reductase inhibitors and the increased risk of psoriasis (odds ratio [OR] = 1.167, 95% confidence interval [CI] = 1.084-1.257). Similarly, the use of thyroid preparations (OR=1.080, 95% CI=1.026-1.138), nonsteroidal anti-inflammatory and antirheumatic products (OR=1.406, 95% CI=1.037-1.908), anilides (OR=1.379, 95% CI=1.004-1.894), antihistamines for systemic use (OR=1.341, 95% CI=1.104-1.630), and antihypertensives (OR=1.099, 95% CI=1.016-1.190) were associated with an increased risk of psoriasis. We did not find evidence from IVW-MR for other associations.
Conclusions: Our study offers a causal testimony that the intake of HMG CoA reductase inhibitors, thyroid preparations, nonsteroidal anti-inflammatory and antirheumatic products, anilides, antihistamines for systemic use, and antihypertensives will potentially increase the risk of psoriasis.
References
Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263-271. DOI: 10.1016/S0140-6736(07)61128-3. PMID: 17658397.
Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301-1315. DOI: 10.1016/S0140-6736(20)32549-6. PMID: 33812489.
Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205-212. DOI: 10.1111/jdv.13854. PMID: 27573025.
Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM; Global Psoriasis Atlas. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. DOI: 10.1136/bmj.m1590. PMID: 32467098. PMCID: PMC7254147.
Fleming P, Bai JW, Pratt M, Sibbald C, Lynde C, Gulliver WP. The prevalence of anxiety in patients with psoriasis: a systematic review of observational studies and clinical trials. J Eur Acad Dermatol Venereol. 2017;31(5):798-807. DOI: 10.1111/jdv.13891. PMID: 27620704.
Gonzalez J, Cunningham K, Perlmutter J, Gottlieb A. Systematic Review of Health-Related Quality of Life in Adolescents with Psoriasis. Dermatology. 2016;232(5):541-549. DOI: 10.1159/000450826. PMID: 27811471.
Soliman MM. Depressive, anxiety, stress, and insomnia symptoms in patients with psoriasis: a cross-sectional study. Postepy Dermatol Alergol. 2021;38(3):510-519. DOI: 10.5114/ada.2020.98726. PMID: 34377136. PMCID: PMC8330873.
Liang SE, Cohen JM, Ho RS. Psoriasis and suicidality: A review of the literature. Dermatol Ther. 2019;32(1):e12771. DOI: 10.1111/dth.12771. PMID: 30315629.
Basavaraj KH, Ashok NM, Rashmi R, Praveen TK. The role of drugs in the induction and/or exacerbation of psoriasis. Int J Dermatol. 2010;49(12):1351-1361. DOI: 10.1111/j.1365-4632.2010.04570.x. PMID: 21091671.
Fry L, Baker BS. Triggering psoriasis: the role of infections and medications. Clin Dermatol. 2007;25(6):606-615. DOI: 10.1016/j.clindermatol.2007.08.015. PMID: 18021899.
Gisondi P, Fostini AC, Fossà I, Girolomoni G, Targher G. Psoriasis and the metabolic syndrome. Clin Dermatol. 2018;36(1):21-28. DOI: 10.1016/j.clindermatol.2017.09.005. PMID: 29241748.
Zhang L, Wang Y, Qiu L, Wu J. Psoriasis and cardiovascular disease risk in European and East Asian populations: evidence from meta-analysis and Mendelian randomization analysis. BMC Med. 2022;20(1):421. DOI: 10.1186/s12916-022-02617-5. PMID: 36320003. PMCID: PMC9628092.
Karbach S, Hobohm L, Wild J, et al. Impact of Psoriasis on Mortality Rate and Outcome in Myocardial Infarction. J Am Heart Assoc. 2020;9(18):e016956. DOI: 10.1161/JAHA.120.016956. PMID: 32914667. PMCID: PMC7726965.
Wang J, Ke R, Shi W, Yan X, et al. Association between psoriasis and asthma risk: A meta-analysis. Allergy Asthma Proc. 2018;39(2):103-109. DOI: 10.2500/aap.2018.39.4109. PMID: 29490768. PMCID: PMC5827153.
Fu Y, Lee CH, Chi CC. Association of Psoriasis With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. JAMA Dermatol. 2018 Dec 1;154(12):1417-1423. DOI: 10.1001/jamadermatol.2018.3631. PMID: 30422277. PMCID: PMC6583370.
Ungprasert P, Raksasuk S. Psoriasis and risk of incident chronic kidney disease and end-stage renal disease: a systematic review and meta-analysis. Int Urol Nephrol. 2018;50(7):1277-1283. DOI: 10.1007/s11255-018-1868-z. PMID: 29644523.
Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for Mendelian randomization. Stat Methods Med Res. 2017;26(5):2333-2355. DOI: 10.1177/0962280215597579. PMID: 26282889. PMCID: PMC5642006.
Wu Y, Byrne EM, Zheng Z, et al. Genome-wide association study of medication-use and associated disease in the UK Biobank. Nat Commun. 2019;10(1):1891. DOI: 10.1038/s41467-019-09572-5. PMID: 31015401. PMCID: PMC6478889.
Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013;37(7):658-665. DOI: 10.1002/gepi.21758. PMID: 24114802. PMCID: PMC4377079.
Kurilshikov A, Medina-Gomez C, Bacigalupe R, et al. Large-scale association analyses identify host factors influencing human gut microbiome composition. Nat Genet. 2021;53(2):156-165. DOI: 10.1038/s41588-020-00763-1. PMID: 33462485. PMCID: PMC8515199.
Kurki MI, Karjalainen J, Palta P, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature. 2023;613(7944):508-518. DOI: 10.1038/s41586-022-05473-8. PMID: 36653562. PMCID: PMC9849126.
Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693-698. DOI: 10.1038/s41588-018-0099-7. PMID: 29686387. PMCID: PMC6083837.
Burgess S, Davey Smith G, Davies NM, et al. Guidelines for performing Mendelian randomization investigations: update for summer 2023. Wellcome Open Res. 2023;4:186. DOI: 10.12688/wellcomeopenres.15555.3. PMID: 32760811. PMCID: PMC7384151.
Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017;32(5):377-389. DOI: 10.1007/s10654-017-0255-x. PMID: 28527048. PMCID: PMC5506233.
Kim GK, Del Rosso JQ. Drug-provoked psoriasis: is it drug induced or drug aggravated?: understanding pathophysiology and clinical relevance. J Clin Aesthet Dermatol. 2010;3(1):32-38. PMID: 20725536. PMCID: PMC2921739.
Balak DM, Hajdarbegovic E. Drug-induced psoriasis: clinical perspectives. Psoriasis (Auckl). 2017;7:87-94. DOI: 10.2147/PTT.S126727. PMID: 29387611. PMCID: PMC5774610.
Shirinsky IV, Shirinsky VS. Efficacy of simvastatin in plaque psoriasis: A pilot study. J Am Acad Dermatol. 2007;57(3):529-531. DOI: 10.1016/j.jaad.2007.05.040. PMID: 17707157.
Socha M, Pietrzak A, Grywalska E, Pietrzak D, et al. The effect of statins on psoriasis severity: a meta-analysis of randomized clinical trials. Arch Med Sci. 2019;16(1):1-7. DOI: 10.5114/aoms.2019.90343. PMID: 32051699. PMCID: PMC6963135.
Ramessur R, Gill D. The effect of statins on severity of psoriasis: A systematic review. Indian J Dermatol Venereol Leprol. 2017;83(2):154-161. DOI: 10.4103/0378-6323.188655. PMID: 27549870.
Ibrahim AM, Attwa EM, Benjuma HH. The exacerbating effect of atorvastatin on psoriasis. Dermatol Ther. 2022;35(8):e15603. DOI: 10.1111/dth.15603. PMID: 35644872.
Cozzani E, Scaparro M, Parodi A. A case of psoriasis worsened by atorvastatin. J Dermatol Case Rep. 2009;3(4):60-1. DOI: 10.3315/jdcr.2009.1037. PMID: 21886735. PMCID: PMC3163346.
Jacobi TC, Highet A. A clinical dilemma while treating hypercholesterolaemia in psoriasis. Br J Dermatol. 2003;149(6):1305-1306. DOI: 10.1111/j.1365-2133.2003.05675.x. PMID: 14674922.
Saraswat A, Saraswat M. Pustular exacerbation of psoriasis due to fexofenadine. Clin Exp Dermatol. 2006;31(3):477-478. DOI: 10.1111/j.1365-2230.2006.02104.x. PMID: 16681618.
Navaratnam AE, Gebauer KA. Terfenadine-induced exacerbation of psoriasis. Clin Exp Dermatol. 1990;15(1):78. DOI: 10.1111/j.1365-2230.1990.tb02035.x. PMID: 1968794.
Cira CI, Carsote M, Nistor C, Petca A, Petca RC, Sandru F. Conundrum for Psoriasis and Thyroid Involvement. Int J Mol Sci. 2023;24(5):4894. DOI: 10.3390/ijms24054894. PMID: 36902323. PMCID: PMC10003398.
Valduga JAG, Rebeiko LB, Skare TL. Prevalence of Hashimoto's thyroiditis in psoriasis patients. Rev Assoc Med Bras (1992). 2021;67(1):52-57. DOI: 10.1590/1806-9282.67.01.20200274. PMID: 34161490.
Alidrisi HA, Al Hamdi K, Mansour AA. Is There Any Association Between Psoriasis and Hashimoto's Thyroiditis? Cureus. 2019;11(3):e4269. DOI: 10.7759/cureus.4269. PMID: 31157131. PMCID: PMC6529052.
Kim HN, Han K, Song SW, Lee JH. Hypertension and risk of psoriasis incidence: An 11-year nationwide population-based cohort study. PLoS One. 2018;13(8):e0202854. DOI: 10.1371/journal.pone.0202854. PMID: 30142208. PMCID: PMC6108501.
Armstrong AW, Lin SW, Chambers CJ, Sockolov ME, Chin DL. Psoriasis and hypertension severity: results from a case-control study. PLoS One. 2011;6(3):e18227. DOI: 10.1371/journal.pone.0018227. PMID: 21479272. PMCID: PMC3066207.
Brauchli YB, Jick SS, Curtin F, Meier CR. Association between beta-blockers, other antihypertensive drugs and psoriasis: population-based case-control study. Br J Dermatol. 2008;158(6):1299-1307. DOI: 10.1111/j.1365-2133.2008.08563.x. PMID: 18410416.
Wilkin J. Exacerbation of psoriasis during clonidine therapy. Arch Dermatol. 1981;117(1):4. PMID: 7458381.
Takehara Y, Igawa K, Satoh T, Yokozeki H. Psoriasiform eruption induced by alpha1-adrenergic blocker, urapidil. J Eur Acad Dermatol Venereol. 2007;21(4):577-578. DOI: 10.1111/j.1468-3083.2006.01977.x. PMID: 17374017.
Wu S, Han J, Qureshi AA. Use of aspirin, non-steroidal anti-inflammatory drugs, and acetaminophen (paracetamol), and risk of psoriasis and psoriatic arthritis: a cohort study. Acta Derm Venereol. 2015;95(2):217-223. DOI: 10.2340/00015555-1855. PMID: 24691893. PMCID: PMC4183729.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Zhichen Li, Haobin Zhou, Chuxian Hu, Zechao Lu, Zechu Lu, Huayao Zhang
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
